Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 984-974-0000
Fax+1 919-843-6949
Dr. Pecot is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Vanderbilt University Medical CenterResidency, Internal Medicine, 2006 - 2009
University of Miami Leonard M. Miller School of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2013 - 2025
TX State Medical License 2009 - 2015
TN State Medical License 2008 - 2010
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - 11 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01 - 1 citationsSpon1+ inflammatory monocytes promote collagen remodeling and lung cancer metastasis through lipoprotein receptor 8 signaling.Kristina M Whately, Nisitha Sengottuvel, Lincy Edatt, Sonal Srivastava, Allison T Woods
JCI Insight. 2024-05-08
Press Mentions
Carolina Cancer Experts Available for InterviewsMay 19th, 2023- Newsworthy from the School of Medicine, Week of August 19 – 25August 25th, 2021
- UNC Researchers Find 'Vulnerability' in Lung Cancer; Could Lead to New TreatmentsSeptember 25th, 2020
- Join now to see all
Grant Support
- Circle RNA Regulation of Lung Cancer MetastasisUNIV OF NORTH CAROLINA CHAPEL HILL2023–2028
- Ligand-Directed KRAS G12V Mutant-Specific TherapeuticsENFUEGO THERAPEUTICS INC.2023–2026
- Ligand-Directed KRAS G12V Mutant-Specific TherapeuticsENFUEGO THERAPEUTICS INC.2023–2026
- Ligand-Directed KRAS G12V Mutant-Specific TherapeuticsENFUEGO THERAPEUTICS INC.2023–2026
- Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin MatricesUNIV OF NORTH CAROLINA CHAPEL HILL2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
